Acadia Pharmaceuticals | ACAD - Current Liabilities



Acadia Pharmaceuticals reported $330.02M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Acadia Pharmaceuticals USD 330.02M 27.49M Jun/2025
ALKERMES USD 505.96M 62.23M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 225.22M Jun/2025
Biogen USD 3.18B 2.11B Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Corcept Therapeutics USD 144.66M 1.6M Jun/2025
Cytokinetics USD 131.06M 28.66M Jun/2025
Eisai JPY 411.61B 39.31B Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Incyte USD 1.28B 608.18M Jun/2025
J&J USD 56.9B 6.58B Mar/2025
Moderna USD 1.57B 32M Jun/2025
Neurocrine Biosciences USD 546.3M 23.4M Jun/2025
Pfizer USD 37.73B 1.27B Jun/2025
Prothena USD 67.81M 19.31M Jun/2025
PTC Therapeutics USD 627.81M 32.42M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025